home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Pier Shareware 6
/
The_Pier_Shareware_Number_6_(The_Pier_Exchange)_(1995).iso
/
026
/
med9410a.zip
/
M94A0124.TXT
< prev
next >
Wrap
Text File
|
1994-10-01
|
2KB
|
40 lines
Document 0124
DOCN M94A0124
TI Activity of liposomal amphotericin B (AmBisome) against Leishmania
infantum and tissue distribution in mice.
DT 9412
AU Gradoni L; Davidson RN; Orsini S; Betto P; Giambenedetti M; Laboratorio
di Parassitologia, Istituto Superiore di Sanita,; Rome, Italy.
SO J Drug Target. 1993;1(4):311-6. Unique Identifier : AIDSLINE
MED/94348809
AB Preliminary observations have shown that AmBisome, a liposomal
formulation of amphotericin B (Vestar Inc.), is effective and non-toxic
in animal and human visceral leishmaniasis. The activity of multiple
doses of this drug on Leishmania infantum, in BALB/c mice was
investigated, and amphotericin B concentration in liver and spleen was
determined. Groups of infected mice were treated intravenously with 3,
5, or 7 doses of AmBisome (3 mg/kg) over 3, 10 and 25 days,
respectively. The antileishmanial activity of the drug was compared with
that of meglumine antimoniate (28 mg Sbv/kg per day over 21 days). Three
consecutive daily doses of AmBisome were sufficient to clear all
parasites from the liver of mice, while antimony did so only after 21
doses. Twenty-four-48 h after their last dose all the AmBisome-treated
mice showed very high amphotericin B concentrations in liver (61.2-76.2
micrograms/g) and spleen (39.8-72.1 micrograms/g) with no overt signs of
toxicity. Mice that received 2 or 4 doses at intervals of 5 to 8 days,
maintained drug levels as high as those detected after 3 consecutive
doses over 11 and 26 days, respectively. This should enable visceral
leishmaniasis treatment on an intermittent or outpatient basis, thereby
reducing overall treatment costs.
DE Amphotericin B/PHARMACOKINETICS/TOXICITY/*THERAPEUTIC USE Animal
Hamsters Human HIV Infections/COMPLICATIONS Infant, Newborn
*Leishmania infantum Leishmaniasis, Visceral/COMPLICATIONS/*DRUG
THERAPY/PARASITOLOGY Liposomes Liver/METABOLISM Meglumine/THERAPEUTIC
USE Mice Mice, Inbred BALB C Organometallic Compounds/THERAPEUTIC USE
Spleen/METABOLISM Support, Non-U.S. Gov't Tissue Distribution JOURNAL
ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).